Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Tunis Med ; 92(11): 674-7, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25867149

RESUMO

BACKGROUND: Bronchiolitis is a public health problem in the word and in Tunisia. Nebulized hypertonic saline seems to have some benefits in bronchiolitis. The aim of this study is to evaluate the efficacy of nebulized 5% hypertonic saline alone or mixed with epinephrine in bronchiolitis as measured by improvement in clinical score, oxygen saturation or reduction in duration of hospitalization. METHODS: This prospective, double blind, placebo controlled, randomized clinical trial was performed at Children's Hospital of Tunis from February 2012 to Mars 2012. A total of 94 patients less than 12 months of age with diagnosis of moderately severe bronchiolitis were enrolled and assigned to receive 5% nebulized hypertonic saline, mixed 5% hypertonic saline with standard epinephrine 0,1% or normal saline (placebo) at admission and every 4 hours during hospitalization. RESULTS: There were no significant difference between nebulized 5% hypertonic saline, mixed 5% hypertonic saline with epinephrine or normal saline at baseline, T30 min, T60 min, and T120 min after start study in Wang severity score, oxygen saturation in room air, rate respiratory and heart rate. There was no difference in duration of hospitalization. CONCLUSION: Nebulized 5% hypertonic saline or mixed 5% hypertonic saline with epinephrine are safety but does not appear effective in treating moderately ill infants with the first acute bronchiolitis.


Assuntos
Bronquiolite/tratamento farmacológico , Epinefrina/administração & dosagem , Nebulizadores e Vaporizadores , Solução Salina Hipertônica/administração & dosagem , Administração por Inalação , Bronquiolite/epidemiologia , Relação Dose-Resposta a Droga , Epinefrina/efeitos adversos , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Solução Salina Hipertônica/efeitos adversos , Tunísia/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA